Our results demonstrate that the combination of low-dose JNKi and TRAIL drastically reduces cell viability in adherent, bulk tumor cells (Figure 3B) and, to an even larger degree, in CSC-enriched spheres (Figure 3C), which are intrinsically more resistant to TRAIL (Figure 3A). Here, TNFSF10 is linked to neoplasm.